凯莱拉治疗
KLRA
11.25
-0.46
-3.93%
凯莱拉治疗
US · KLRA
#3073 按市值排名
上市于 2026
11.25
-0.46
-3.93%
实时 - 追踪5344个代码 - 心跳于8秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 99.29% -0.06pp
- 机构数量
- 120
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund45.26%
Mutual Fund20.59%
Hedge Fund16.41%
Public Company9.38%
Government Pension Fund5.66%
Private Company1.97%
Other0.68%
主要股东 截至 2026-06-30
Bain Capital, LP
20.25% · 26.26M 股
Bain Capital Life Sciences Investors, LLC
17.42% · 22.58M 股
Jiangsu Hengrui Pharmaceuticals Co.,Ltd
8.88% · 11.51M 股
RTW Investments, LP
8.31% · 10.78M 股
Canada Pension Plan Investment Board
5.63% · 7.30M 股
Atlas Venture Advisors, Inc.
3.99% · 5.17M 股
FMR
3.06% · 3.97M 股
BlackRock
3.03% · 3.93M 股
T. Rowe Price Group, Inc.
2.73% · 3.53M 股
Citadel Advisors LLC
2.50% · 3.24M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪45份申报 · 23次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Bain Capital, LP | -- | 20.25% |
| Bain Capital Life Sciences Investors, LLC | -- | 17.42% |
| Ronald Renaud | Chief Executive Officer | 0.03% |
| John Milligan | Independent Non-Employee Chairman | -- |
| Canada Pension Plan Investment Board | -- | -- |
| Christopher Hite | Independent Director | -- |
| Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | -- |
| Adam Koppel | Independent Director | -- |
| Martin MacKay | Independent Director | -- |
| Bain Capital Investors, LLC | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-06 | Nur Nicholson | -- | Other Derivative Acquisition | +220,000 | $16.23 |
| 2026-07-05 | Kathleen Tregoning | Chief Corporate Affairs Officer | Other Derivative Acquisition | +175,000 | $23.30 |
| 2026-06-08 | Ronald Renaud | Chief Executive Officer | Derivative Exercise and Retained | +38,094 | $5.25 |
| 2026-04-19 | Bain Capital, LP | -- | Private Acquisition | +8,398,438 | $16.00 |
| 2026-04-19 | Bain Capital, LP | -- | Derivative Exercise and Retained | +17,857,143 | -- |
| 2026-04-19 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Derivative Exercise and Retained | +11,511,852 | -- |
| 2026-04-19 | RTW Investments, LP | -- | Private Acquisition | +500,000 | $16.00 |
| 2026-04-19 | RTW Investments, LP | -- | Derivative Exercise and Retained | +10,276,820 | -- |
| 2026-04-19 | Bain Capital Life Sciences Investors, LLC | -- | Private Acquisition | +1,562,500 | $16.00 |
| 2026-04-19 | Bain Capital Life Sciences Investors, LLC | -- | Derivative Exercise and Retained | +21,020,768 | -- |
| 2026-04-15 | John Milligan | Independent Non-Employee Chairman | Other Derivative Acquisition | +38,300 | $16.00 |
| 2026-04-15 | John Milligan | Independent Non-Employee Chairman | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Canada Pension Plan Investment Board | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Christopher Hite | Independent Director | Other Derivative Acquisition | +38,300 | $16.00 |
| 2026-04-15 | Christopher Hite | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Ronald Renaud | Chief Executive Officer | Other Derivative Acquisition | +600,000 | $16.00 |
| 2026-04-15 | Ronald Renaud | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-04-15 | Adam Koppel | Independent Director | Other Derivative Acquisition | +38,300 | $16.00 |
| 2026-04-15 | Martin MacKay | Independent Director | Other Derivative Acquisition | +38,300 | $16.00 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
凯莱拉治疗 讨论区 0 条评论